SEC Form 4 · accession 0000886163-18-000132

LIGAND PHARMACEUTICALS INC · LGND

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — SVP, Gen. Counsel & Secretary

Period of report

Sep 4, 2018

Accepted (ET)

Sep 5, 2018 · 8:00 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000886163

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Sep 4, 2018	M	469	$21.92	A	28,232	D
Common Stock^F1	Sep 4, 2018	M	5,985	$74.42	A	34,217	D
Common Stock^F1	Sep 4, 2018	M	7,077	$56.26	A	41,294	D
Common Stock^F1	Sep 4, 2018	M	5,886	$85.79	A	47,180	D
Common Stock^F1,F2	Sep 4, 2018	S	19,417	$254.9861	D	27,763	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F1,F3	$56.26	Sep 4, 2018	M	7,077	D	—	Feb 10, 2025	Common Stock	7,077	3,292	D
Employee Stock Option (right to buy)^F1,F4	$74.42	Sep 4, 2018	M	5,985	D	—	Feb 12, 2024	Common Stock	5,985	1,931	D
Employee Stock Option (right to buy)^F1,F5	$85.79	Sep 4, 2018	M	5,886	D	—	Feb 11, 2026	Common Stock	5,886	4,577	D
Non-Qualified Stock Option (right to buy)^F1,F6	$21.92	Sep 4, 2018	M	469	D	—	Feb 15, 2023	Common Stock	469	0	D

F1The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2018, in accordance with Rule 10b5-1.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $252.85 to $256.59, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/10/15.
F4Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/12/14.
F5Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/11/16.
F6Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/15/13.